Skinos introduces Exciplex, a device for treating autoimmune skin diseases
Summary
The Exciplex is a handheld monochromatic Excimer Light platform designed to address a range of autoimmune skin conditions.
Skinos, a provider of aesthetic services, has unveiled its latest innovation, the Exciplex. This device, approved by the US Food and Drug Administration (FDA), represents a significant advancement in the treatment of autoimmune skin diseases.
The Exciplex is a handheld monochromatic Excimer Light platform designed to address a range of autoimmune skin conditions.
It emits light at 308nm, a wavelength optimised for treating chronic autoimmune skin diseases such as Vitiligo, Psoriasis, Alopecia Areata, Mycosis Fungoids, and Atopic Dermatitis.
Shruti Gupta, Medical Director & Dermatologist at Skinos emphasised its clinical efficiency and widespread recognition among dermatologists worldwide.
One of the key benefits of the Exciplex is its ability to provide quick and effective treatmens.
Conditions like Vitiligo and Psoriasis can often lead to social withdrawal and stigma, contributing to stress and anxiety among affected individuals.
Gupta highlighted the importance of Excimer Light Therapy in addressing these visible skin conditions,
The Exciplex offers numerous advantages for both patients and doctors.
It is the smallest Monochromatic Excimer Light platform available, allowing for the treatment of localized autoimmune skin conditions and dermatological indications.
With a spot size of 25 square centimeters, the device can target large areas while also accommodating smaller lesions using reduction tips.
Its lightweight and portable design, coupled with an intuitive touchscreen interface.
The Exciplex does not require any consumables, offering a cost-effective and environmentally friendly treatment option.
Gupta emphasised the device’s safety and effectiveness, citing numerous clinical studies supporting its efficacy in treating autoimmune skin conditions.
Elon Musk forms several ‘X Holdings’ companies to fund potential Twitter buyout
3 Mins Read
Thursday’s filing dispelled some doubts, though Musk still has work to do. He and his advisers will spend the coming days vetting potential investors for the equity portion of his offer, according to people familiar with the matter